Bulger T - Search Results

1

A cut above: the rising Caesarean section rate in New Zealand.

Bulger T, Howden-Chapman P, Stone P. Bulger T, et al. N Z Med J. 1998 Feb 13;111(1059):30-3. N Z Med J. 1998. PMID: 9506669

2

Administration of anaesthetic triggering agents to patients tested malignant hyperthermia normal and their relatives in New Zealand: an update.

Frei D, Stowell KM, Langton EE, McRedmond L, Pollock NA, Bulger TF. Frei D, et al. Among authors: bulger tf. Anaesth Intensive Care. 2017 Sep;45(5):611-618. doi: 10.1177/0310057X1704500512. Anaesth Intensive Care. 2017. PMID: 28911291

3

Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update.

Barnes C, Stowell KM, Bulger T, Langton E, Pollock N. Barnes C, et al. Among authors: bulger t. Anaesth Intensive Care. 2015 Jan;43(1):98-104. doi: 10.1177/0310057X1504300115. Anaesth Intensive Care. 2015. PMID: 25579296

4

Malignant hyperthermia: a review.

Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Rosenberg H, et al. Among authors: bulger t. Orphanet J Rare Dis. 2015 Aug 4;10:93. doi: 10.1186/s13023-015-0310-1. Orphanet J Rare Dis. 2015. PMID: 26238698 Free PMC article. Review.

5

Masseter muscle rigidity and the role of DNA analysis to confirm malignant hyperthermia susceptibility.

Hudig K, Pollock N, Bulger T, Machon RG, Woodhead A, Schiemann AH, Stowell KM. Hudig K, et al. Among authors: bulger t. Anaesth Intensive Care. 2019 Jan;47(1):60-68. doi: 10.1177/0310057X18811816. Epub 2019 Feb 15. Anaesth Intensive Care. 2019. PMID: 30864471

6

A genetic mystery in malignant hyperthermia 'solved'?

Schiemann AH, Bjorksten AR, Gillies RL, Hockey BM, Ball C, Pollock N, Bulger T, Stowell KM. Schiemann AH, et al. Among authors: bulger t. Br J Anaesth. 2018 Sep;121(3):681-682. doi: 10.1016/j.bja.2018.05.051. Epub 2018 Jun 20. Br J Anaesth. 2018. PMID: 30115273 Free article. No abstract available.

7

Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents.

Pollock N, Langton EE, Stowell KM, Bulger TF. Pollock N, et al. Among authors: bulger tf. Anaesth Intensive Care. 2011 Sep;39(5):887-94. doi: 10.1177/0310057X1103900514. Anaesth Intensive Care. 2011. PMID: 21970134

8

Preparation of Datex-Ohmeda Aestiva and Aisys anaesthetic machines for use in malignant hyperthermia susceptible patients.

Jones C, Bennett K, Kim TW, Bulger TF, Pollock N. Jones C, et al. Among authors: bulger tf. Anaesth Intensive Care. 2012 May;40(3):490-7. doi: 10.1177/0310057X1204000315. Anaesth Intensive Care. 2012. PMID: 22577915

9

Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis.

Chan TY, Bulger TF, Stowell KM, Gillies RL, Langton EE, Street NE, Pollock NA. Chan TY, et al. Among authors: bulger tf. Anaesth Intensive Care. 2017 Nov;45(6):707-713. doi: 10.1177/0310057X1704500610. Anaesth Intensive Care. 2017. PMID: 29137581

10

Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.

Parker R, Schiemann AH, Langton E, Bulger T, Pollock N, Bjorksten A, Gillies R, Hutchinson D, Roxburgh R, Stowell KM. Parker R, et al. Among authors: bulger t. J Neuromuscul Dis. 2017;4(2):147-158. doi: 10.3233/JND-170210. J Neuromuscul Dis. 2017. PMID: 28527222 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters